FDA Approves Revolutionary twiist AID System

FDA Approves Revolutionary twiist AID System

In a groundbreaking development for diabetes care, the FDA has recently given clearance to the twiist automated insulin delivery (AID) system, a game-changer designed to empower individuals with type 1 diabetes. Developed in collaboration with Deka, this innovative system is set to revolutionize insulin delivery and glycemic control.

Precision Measuring for Personalized Care

The twiist AID system stands out as the first insulin pump to integrate seamlessly with Tidepool Loop, offering unparalleled precision and customization. Approved for individuals aged 6 and above, this system provides precise microdosing capabilities and allows users to set target glucose levels as low as 87 mg/dL. Moreover, it enables bolusing based on various food types, providing users with greater flexibility and control over their diabetes management.

A Closer Look at the Components

At the core of the twiist AID system lies the Deka insulin pump, a cutting-edge device designed to deliver insulin with unparalleled accuracy. Unlike traditional pumps, the Deka pump directly measures both the volume and flow of insulin, ensuring precise dosing with each micro-dose. Additionally, the pump boasts a reusable design, with the reservoir capable of holding 300 units of rapid-acting insulin.

Complementing the Deka pump is the Tidepool Loop algorithm, a sophisticated software solution that automates insulin delivery based on continuous glucose monitor (CGM) readings. This innovative algorithm offers users the flexibility to build their own AID system by combining a wide range of CGM sensors and insulin delivery devices. With Tidepool Loop, users can set lower glucose targets and adjust bolus levels to suit their individual needs, promoting tighter glycemic control and improved health outcomes.

Empowering Users with Choice and Flexibility

The approval of the twiist AID system marks a significant milestone in the field of diabetes management, offering users greater choice, customization, and affordability. With the option to set lower glucose targets and tailor bolus delivery based on food types, users can achieve tighter glycemic control and increase their time in range.

Moreover, the system's innovative microdosing capabilities allow for more precise insulin delivery, ensuring optimal glycemic control with minimal risk of hypoglycemia. By empowering users with choice and flexibility, the twiist AID system represents a major step forward in diabetes care, setting a new standard for precise and dependable insulin delivery.

Looking Ahead

While specific details regarding the launch date of the twiist AID system are yet to be announced, Sequel Med Tech, the company behind the system, aims to make it available in pharmacies with a pay-as-you-go model for greater accessibility and affordability. By offering insulin delivery systems in pharmacies, Sequel hopes to remove cost as a barrier for individuals seeking to start on an AID system, allowing them to get started quickly and without making a long-term commitment.

Back to blog